TY - JOUR
T1 - Diabetes, prediabetes, and brain volumes and subclinical cerebrovascular disease on MRI
T2 - The atherosclerosis risk in communities neurocognitive study (ARIC-NCS)
AU - Schneider, Andrea L.C.
AU - Selvin, Elizabeth
AU - Sharrett, A. Richey
AU - Griswold, Michael
AU - Coresh, Josef
AU - Jack, Clifford R.
AU - Knopman, David
AU - Mosley, Thomas
AU - Gottesman, Rebecca F.
N1 - Funding Information:
and participants of the ARIC Study for important contributions. Funding. The ARIC Study is carried out as a collaborativestudysupportedbyNationalHeart, Lung, and Blood Institute (NHLBI) contracts (HH-SN-268201100005C, HH-SN-268201100006C, HH-SN-268201100007C, HH-SN-268201100008C, HH-SN-268201100009C, HH-SN-268201100010C, HH-SN-268201100011C, and HH-SN-268201 100012C). The ARIC-NCS was supported by NHLBI grants U01-HL-096812, U01-HL-096814, U01-HL-096899, U01-HL-096902, and U01-HL-096917. A.L.C.S. is supported by the National Institute of Neurological Disorders and Stroke through an administrative supplement to award R25-NS-065729. E.S. was supported by National Institute of Diabetes and Digestive and Kidney Diseases grants K24-DK-106414 and R01-DK-089174. Duality of Interest. D.K. serves on a data safety monitoring board for Lundbeck and for the Dominantly Inherited Alzheimer Network (DIAN) study and is an investigator in clinical trials sponsored by Biogen, TauRX Therapeutics, and Eli Lilly. R.F.G. is an associate editor for the journal Neurology. No other potential conflicts of interest relevant to this article were reported. Author Contributions. A.L.C.S. performed the data analysis, contributed to the discussion, and wrote the manuscript. E.S., A.R.S., M.G., J.C., C.R.J., D.K., and T.M. contributed to the discussion and reviewedand edited the manuscript. R.F.G. performed thedataanalysis,contributedtothediscussion,and reviewed and edited the manuscript. A.L.C.S. and R.F.G.aretheguarantorsofthisworkand,assuch, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. Parts of this study were presented in abstract form at the 141st Annual Meeting of the American Neurological Association, Baltimore, MD, 16–18 October 2016.
Publisher Copyright:
© 2017 by the American Diabetes Association.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - OBJECTIVE To examine the associations of prediabetes, diabetes, and diabetes severity (as assessed byHbA1c and diabetes duration)with brain volumes and vascular pathology on brainMRI and to assess whether the associations of diabetes with brain volumes are mediated by brain vascular pathology. RESEARCH DESIGN AND METHODS Cross-sectional study of 1,713 participants in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) (mean age 75 years, 60% female, 27% black, 30% prediabetes, and 35% diabetes) who underwent 3T brain MRI scans in 2011-2013. Participants were categorized by diabetes-HbA1c status as without diabetes (<5.7% [reference]), with prediabetes (5.7 to <6.5%), and with diabetes ([defined as prior diagnosis or HbA1c ≥6.5%] <7.0% vs. ≥7.0%), with further stratification by diabetes duration (<10 vs. ≥10 years). RESULTS In adjusted analyses, comparedwith participantswithout diabetes and HbA1c <5.7%, participants with prediabetes and thosewith diabetes and HbA1c <7.0%did not have significantly different brain volumes or vascular pathology (all P > 0.05), but those with diabetes and HbA1c ≥7.0% had smaller total brain volume (b 20.20 SDs, 95% CI20.31,20.09), smaller regional brain volumes (including frontal, temporal, occipital, and parietal lobes; deep gray matter; Alzheimer disease signature region; and hippocampus [all P < 0.05]), and increased burden of white matter hyperintensities (WMH) (P = 0.016). Among participants with diabetes, those with HbA1c ≥7.0% had smaller total and regional brain volumes and an increased burden of WMH (all P < 0.05) compared with those with HbA1c <7.0%. Similarly, participants with longer duration of diabetes (≥10 years) had smaller brain volumes and higher burden of lacunes (all P < 0.05) than those with a diabetes duration <10 years. We found no evidence for mediation by WMH in associations of diabetes with smaller brain volumes by structural equation models (all P > 0.05). CONCLUSIONS More-severe diabetes (defined by higher HbA1c and longer disease duration) but not prediabetes or less-severe diabetes was associated with smaller brain volumes and an increased burden of brain vascular pathology. No evidence was found that associations of diabetes with smaller brain volumes are mediated by brain vascular pathology, suggesting that other mechanismsmay be responsible for these associations.
AB - OBJECTIVE To examine the associations of prediabetes, diabetes, and diabetes severity (as assessed byHbA1c and diabetes duration)with brain volumes and vascular pathology on brainMRI and to assess whether the associations of diabetes with brain volumes are mediated by brain vascular pathology. RESEARCH DESIGN AND METHODS Cross-sectional study of 1,713 participants in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) (mean age 75 years, 60% female, 27% black, 30% prediabetes, and 35% diabetes) who underwent 3T brain MRI scans in 2011-2013. Participants were categorized by diabetes-HbA1c status as without diabetes (<5.7% [reference]), with prediabetes (5.7 to <6.5%), and with diabetes ([defined as prior diagnosis or HbA1c ≥6.5%] <7.0% vs. ≥7.0%), with further stratification by diabetes duration (<10 vs. ≥10 years). RESULTS In adjusted analyses, comparedwith participantswithout diabetes and HbA1c <5.7%, participants with prediabetes and thosewith diabetes and HbA1c <7.0%did not have significantly different brain volumes or vascular pathology (all P > 0.05), but those with diabetes and HbA1c ≥7.0% had smaller total brain volume (b 20.20 SDs, 95% CI20.31,20.09), smaller regional brain volumes (including frontal, temporal, occipital, and parietal lobes; deep gray matter; Alzheimer disease signature region; and hippocampus [all P < 0.05]), and increased burden of white matter hyperintensities (WMH) (P = 0.016). Among participants with diabetes, those with HbA1c ≥7.0% had smaller total and regional brain volumes and an increased burden of WMH (all P < 0.05) compared with those with HbA1c <7.0%. Similarly, participants with longer duration of diabetes (≥10 years) had smaller brain volumes and higher burden of lacunes (all P < 0.05) than those with a diabetes duration <10 years. We found no evidence for mediation by WMH in associations of diabetes with smaller brain volumes by structural equation models (all P > 0.05). CONCLUSIONS More-severe diabetes (defined by higher HbA1c and longer disease duration) but not prediabetes or less-severe diabetes was associated with smaller brain volumes and an increased burden of brain vascular pathology. No evidence was found that associations of diabetes with smaller brain volumes are mediated by brain vascular pathology, suggesting that other mechanismsmay be responsible for these associations.
UR - http://www.scopus.com/inward/record.url?scp=85033223382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033223382&partnerID=8YFLogxK
U2 - 10.2337/dc17-1185
DO - 10.2337/dc17-1185
M3 - Article
C2 - 28916531
AN - SCOPUS:85033223382
SN - 0149-5992
VL - 40
SP - 1514
EP - 1521
JO - Diabetes care
JF - Diabetes care
IS - 11
ER -